Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4908562 | 0.92 | TRPV1 (0.45) | NPC1RAB9ASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL4917884 | 0.90 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL4920519 | 0.88 | TRPV1 (0.56) | TRPV1 | |
| SCHEMBL4916627 | 0.84 | TRPV1 (0.46) | NPC1RAB9ASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL4915071 | 0.84 | TRPV1 (0.51) | TRPV1ABCG2 | |
| SCHEMBL14169434 | 0.84 | TRPV1 (0.47) | TRPV1ABCG2 | |
| SCHEMBL14307898 | 0.83 | TRPV1 (0.46) | TRPV1ABCG2 | |
| SCHEMBL4916894 | 0.83 | TRPV1 (0.61) | TRPV1ABCG2 | |
| SCHEMBL4916515 | 0.83 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL4911837 | 0.82 | TRPV1 (0.45) | NPC1RAB9ASMN1; SMN2L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153857-A1 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-06-26 | — | — | US | claimed |
| US-7329664-B2 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-02-12 | — | — | US | claimed |
| US-20050215575-A1 | (4-Isopropyl-phenyl)-[2-(tetrahydro-pyran-4-yloxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine; 2-{4-[2-benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ylamino]-phenyl}-2-methyl-propionitrile; treating conditions related to capsaicin receptor activation | NEUROGEN CORPORATION | 2005-09-29 | — | — | US | claimed |
| EP-1471910-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN RECEPTORS | NEUROGEN CORPORATION (US) | 2004-11-03 | — | — | EP | claimed |
| WO-2003062209-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN | NEUROGEN CORPORATION (US) | 2003-07-31 | — | — | WO | claimed |
| US-20080153857-A1 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153857-A1 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153857-A1 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-06-26 | — | — | US | disclosed |
| US-7329664-B2 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329664-B2 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329664-B2 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-7304059-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304059-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304059-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060173003-A1 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-08-03 | — | — | US | disclosed |
| US-7074799-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-07-11 | — | — | US | disclosed |
| US-20050215575-A1 | (4-Isopropyl-phenyl)-[2-(tetrahydro-pyran-4-yloxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine; 2-{4-[2-benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ylamino]-phenyl}-2-methyl-propionitrile; treating conditions related to capsaicin receptor activation | NEUROGEN CORPORATION | 2005-09-29 | — | — | US | disclosed |
| US-20040142958-A1 | Combination therapy for the treatment of pain | NEUROGEN CORPORATION | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | PIGS, HRH4, GPR88 | NPC1 1987/4885RAB9A 923/4885SMN1; SMN2 2871/4885 |
| US-20040142958-A1 | Combination therapy for the treatment of pain | OPRK1, OPRL1, OPRM1 | NPC1 2064/4885RAB9A 4200/4885SMN1; SMN2 842/4885 |
| US-20050215575-A1 | (4-Isopropyl-phenyl)-[2-(tetrahydro-pyran-4-yloxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine; 2-{4-[2-benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ylamino]-phenyl}-2-methyl-propionitrile; treating conditions related to capsaicin receptor activation | TRPV1, CNR2, NTRK1 | NPC1 1959/4885RAB9A 2090/4885SMN1; SMN2 1464/4885 |
| US-20060173003-A1 | Substituted quinazolin-4-ylamine analogues | PIGS, HRH4, GPR88 | NPC1 1987/4885RAB9A 923/4885SMN1; SMN2 2871/4885 |
| US-20080153857-A1 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | GPR27, GPR88, MUSK | NPC1 2852/4885RAB9A 926/4885SMN1; SMN2 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.